Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis
Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences
Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology
Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology
Kezar Life Sciences to Participate in Upcoming Virtual Investor Conferences
